[Skip to Navigation]
Comment & Response
December 2017

ADS 5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia—Reply

Author Affiliations
  • 1University of Florida, Center for Movement Disorders & Neurorestoration, Gainesville
JAMA Neurol. 2017;74(12):1508. doi:10.1001/jamaneurol.2017.3211

In Reply Pahwa and Hauser raise legitimate concerns based on my Editorial.1 In the EASE LID study, amantadine extended release was found to demonstrate efficacy in a randomized double-blind placebo-controlled design for treatment of levodopa-induced dyskinesias (LID) in Parkinson disease (PD).2 Pahwa and Hauser have expressed concerns over aspects of amantadine therapy that I discussed in the Editorial1 following the EASE LID study and I would like to address each of their comments.

Add or change institution